Gore announced on 3 August 2010 the first clinical cases in Australia involving the Gore DrySeal Sheath. The sheath aids in minimally invasive treatment of patients with abdominal aortic aneurysms utilising the Gore Excluder AAA Endoprosthesis and thoracic aortic aneurysms utilising the Gore TAG Thoracic Endoprosthesis.
The first successful procedures were performed by Thomas Daly, at Westmead Hospital, New South Wales, Alan Bray, at Newcastle Private, New South Wales, and Michael Denton, at Epworth Private Hospital, Victoria. According to Daly, who performed the first clinical case in Australia, during treatment of an emergent, symptomatic abdominal aortic aneurysm, “The haemostasis achieved with the Gore DrySeal Sheath is unsurpassed by any other large diameter commercial sheath. Its versatility reduces patient blood loss while not compromising accessibility.”
The DrySeal Sheath, which was recently released in Australia, is comprised of an innovative haemostatic valve attached to the introducer sheath. The valve is unique in that it is pressurised to create a seal, thereby minimising blood loss and accommodating multiple wires and catheters simultaneously. The valve consists of a silicone outer tube and an inner film tube that create an effective hemostatic seal that easily adapts to the profiles of the inserted devices. The Gore DrySeal Sheath is available in profiles from 12 to 26F, in 2F increments, and has a working length of 28cm.
Gore Aortic Business Leader David Abeyta added, “The Gore DrySeal Sheath is the newest addition to Gore’s world-class portfolio and is further evidence of Gore’s commitment to the development of innovative solutions to address unmet clinical needs in the Australian endovascular market.”